Home

The Korea Herald

Latest news

Most Popular

  1. 1

    Trump picks ex-N. Korea policy official as his principal deputy national security adviser

    Trump picks ex-N. Korea policy official as his principal deputy national security adviser
  2. 2

    S. Korea not to attend Sado mine memorial: foreign ministry

    S. Korea not to attend Sado mine memorial: foreign ministry
  3. 3

    First snow to fall in Seoul on Wednesday

    First snow to fall in Seoul on Wednesday
  4. 4

    Man convicted after binge eating to avoid military service

    Man convicted after binge eating to avoid military service
  5. 5

    Wealthy parents ditch Korean passports to get kids into international school

    Wealthy parents ditch Korean passports to get kids into international school
  1. 6

    Toxins at 622 times legal limit found in kids' clothes from Chinese platforms

    Toxins at 622 times legal limit found in kids' clothes from Chinese platforms
  2. 7

    Actor Jung Woo-sung admits to being father of model Moon Ga-bi’s child

    Actor Jung Woo-sung admits to being father of model Moon Ga-bi’s child
  3. 8

    [Weekender] Korea's traditional sauce culture gains global recognition

    [Weekender] Korea's traditional sauce culture gains global recognition
  4. 9

    BLACKPINK's Rose stays at No. 3 on British Official Singles chart with 'APT.'

    BLACKPINK's Rose stays at No. 3 on British Official Singles chart with 'APT.'
  5. 10

    Korea to hold own memorial for forced labor victims, boycotting Japan’s

    Korea to hold own memorial for forced labor victims, boycotting Japan’s
소아쌤

Financial authorities reverse decision to delist Kyung Nam Pharm

By Korea Herald

Published : Jan. 8, 2019 - 21:55

    • Link copied

South Korea’s Kosdaq Market Committee on Tuesday scrapped Korea Exchange’s plan to delist local pharmaceuticals company Kyung Nam Pharm from the second-tier Kosdaq market, instead giving the company a one-year grace period to improve transparency.

A panel led by the Korea Exchange, the nation’s sole market operator, last week suggested Kyung Nam Pharm be pulled from the Kosdaq market over accounting errors that occurred between financial years 2008 and 2013.

Due to the errors, revenue of 5 billion won ($4.4 million) was misstated, according to KRX.

Milestone KN Fund is the biggest shareholder of Kyung Nam Pharm, holding 12.48 percent of shares.

(Kyung Nam Pharm.) (Kyung Nam Pharm.)

The initial announcement had spurred questions over whether the panel’s decision was fair, drawing comparison to the case of Samsung BioLogics where the same panel agreed to normalize stock transactions of Samsung BioLogics in late December.

The Securities and Futures Commission suspended trading of the bio firm’s shares for a month due to accounting fraud and the company’s chief executive was levied a fine of 16 million won.  

By The Korea Herald staff (khnews@heraldcorp.com)

More from Headlines